Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2016

11.02.2016 | Original Article - Clinical Oncology

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer

verfasst von: Heng Fan, Zhen-Yi Shao, Yuan-Yuan Xiao, Zhi-Hui Xie, Wen Chen, Hua Xie, Guo-You Qin, Nai-Qing Zhao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Glasgow Prognostic Score (GPS) and modified Glasgow Prognostic Score (mGPS) are shown to be reliable prognostic indexes in patients with operable and inoperable non-small cell lung cancer (NSCLC). Considering the difference between the two indexes lies in whether hypoalbuminemia without an elevated C-reactive protein (CRP) is associated with worse survival, this study aims to evaluate the prognostic performance of hypoalbuminemia in patients without an elevated CRP and to compare the prognostic value of GPS and mGPS in patients with operable and inoperable NSCLC.

Methods

The data of 2988 patients were retrospectively collected from the Shanghai Health Information Network. Univariate and multivariate Cox regression was performed to investigate the prognostic effect of albumin, CRP, GPS and mGPS. Restricted cubic spline was also performed to evaluate the relationship between albumin and hazard ratio. Kaplan–Meier survival curves were estimated and compared using the log-rank test. Additional discriminative ability of GPS and of mGPS was evaluated using the area under the curve and Harrell’s concordance index.

Results

Hypoalbuminemia was associated with worse survival in both operable and inoperable patients without an elevated CRP. The Kaplan–Meier survival curve of hypoalbuminemic patients without an elevated CRP was more close to the curve of patients with an elevated CRP and a normal albumin than to the curve of patients with neither of these abnormalities. Multivariate analysis, AUC and C-index all indicated that GPS had a higher prognostic value than mGPS.

Conclusions

Hypoalbuminemia was associated with worse survival in patients with or without an elevated CRP. GPS was superior to mGPS in predicting survival in operable and inoperable NSCLC patients.
Literatur
Zurück zum Zitat Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard G, Damotte D, Régnard J (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142(5):1161–1167CrossRefPubMed Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard G, Damotte D, Régnard J (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142(5):1161–1167CrossRefPubMed
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed
Zurück zum Zitat Ebbert JO, Yang P, Vachon CM, Vierkant RA, Cerhan JR, Folsom AR, Sellers TA (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21(5):921–926CrossRefPubMed Ebbert JO, Yang P, Vachon CM, Vierkant RA, Cerhan JR, Folsom AR, Sellers TA (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21(5):921–926CrossRefPubMed
Zurück zum Zitat Espinosa E, Feliu J, Zamora P, Gonzalez BM, Sanchez JJ, Ordon EA, Espinosa J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12(1–2):67–76CrossRefPubMed Espinosa E, Feliu J, Zamora P, Gonzalez BM, Sanchez JJ, Ordon EA, Espinosa J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12(1–2):67–76CrossRefPubMed
Zurück zum Zitat Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T (1999) Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23(6):584–588CrossRefPubMed Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T (1999) Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23(6):584–588CrossRefPubMed
Zurück zum Zitat Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90(9):1704–1706. doi:10.1038/sj.bjc.6601789 PubMedPubMedCentral Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90(9):1704–1706. doi:10.​1038/​sj.​bjc.​6601789 PubMedPubMedCentral
Zurück zum Zitat Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR (2005) A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 92(10):1834–1836. doi:10.1038/sj.bjc.6602591 CrossRefPubMedPubMedCentral Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR (2005) A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 92(10):1834–1836. doi:10.​1038/​sj.​bjc.​6602591 CrossRefPubMedPubMedCentral
Zurück zum Zitat Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, Kasymjanova G, Kreisman H, Small D (2010) Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 102(7):1113–1122. doi:10.1038/sj.bjc.6605603 CrossRefPubMedPubMedCentral Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, Kasymjanova G, Kreisman H, Small D (2010) Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 102(7):1113–1122. doi:10.​1038/​sj.​bjc.​6605603 CrossRefPubMedPubMedCentral
Zurück zum Zitat Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V (2012) The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 77(2):383–388. doi:10.1016/j.lungcan.2012.04.008 CrossRefPubMed Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V (2012) The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 77(2):383–388. doi:10.​1016/​j.​lungcan.​2012.​04.​008 CrossRefPubMed
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8):706–714. doi:10.1097/JTO.0b013e31812f3c1a CrossRefPubMed Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8):706–714. doi:10.​1097/​JTO.​0b013e31812f3c1a​ CrossRefPubMed
Zurück zum Zitat Hastie T, Tibshirani R (1990) Generalized additive models. Chapman and Hall/CRC, London Hastie T, Tibshirani R (1990) Generalized additive models. Chapman and Hall/CRC, London
Zurück zum Zitat Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22(3):803–810. doi:10.1245/s10434-014-4048-0 CrossRefPubMed Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22(3):803–810. doi:10.​1245/​s10434-014-4048-0 CrossRefPubMed
Zurück zum Zitat Kishi T, Matsuo Y, Ueki N, Iizuka Y, Nakamura A, Sakanaka K, Mizowaki T, Hiraoka M (2015) Pretreatment Modified Glasgow Prognostic Score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 92(3):619–626. doi:10.1016/j.ijrobp.2015.02.018 CrossRefPubMed Kishi T, Matsuo Y, Ueki N, Iizuka Y, Nakamura A, Sakanaka K, Mizowaki T, Hiraoka M (2015) Pretreatment Modified Glasgow Prognostic Score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 92(3):619–626. doi:10.​1016/​j.​ijrobp.​2015.​02.​018 CrossRefPubMed
Zurück zum Zitat Koch A, Fohlin H, Sorenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4(3):326–332. doi:10.1097/JTO.0b013e31819578c8 CrossRefPubMed Koch A, Fohlin H, Sorenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4(3):326–332. doi:10.​1097/​JTO.​0b013e31819578c8​ CrossRefPubMed
Zurück zum Zitat McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213. doi:10.1207/S15327914nc392_8 CrossRefPubMed McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213. doi:10.​1207/​S15327914nc392_​8 CrossRefPubMed
Zurück zum Zitat McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22(8):881–886. doi:10.1007/s00384-006-0259-6 CrossRefPubMed McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22(8):881–886. doi:10.​1007/​s00384-006-0259-6 CrossRefPubMed
Zurück zum Zitat Meek CL, Wallace AM, Forrest LM, McMillan DC (2010) The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 29(2):206–209. doi:10.1016/j.clnu.2009.08.013 CrossRefPubMed Meek CL, Wallace AM, Forrest LM, McMillan DC (2010) The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 29(2):206–209. doi:10.​1016/​j.​clnu.​2009.​08.​013 CrossRefPubMed
Zurück zum Zitat Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Taniguchi D, Nagayasu T (2015) Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 47(4):e140–e145. doi:10.1093/ejcts/ezu514 CrossRefPubMed Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Taniguchi D, Nagayasu T (2015) Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 47(4):e140–e145. doi:10.​1093/​ejcts/​ezu514 CrossRefPubMed
Zurück zum Zitat Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ (2015) Prognostic value of the Modified Glasgow Prognostic Score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine (Baltimore) 94(36):e1486. doi:10.1097/MD.0000000000001486 CrossRef Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ (2015) Prognostic value of the Modified Glasgow Prognostic Score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine (Baltimore) 94(36):e1486. doi:10.​1097/​MD.​0000000000001486​ CrossRef
Zurück zum Zitat Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17):2633–2641. doi:10.1016/j.ejca.2011.03.028 CrossRefPubMed Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17):2633–2641. doi:10.​1016/​j.​ejca.​2011.​03.​028 CrossRefPubMed
Zurück zum Zitat Tolia M, Tsoukalas N, Kyrgias G, Mosa E, Maras A, Kokakis I, Liakouli Z, Kouvaris JR, Liaskonis K, Charalampakis N, Pistevou-Gombaki K, Kelekis N, Kouloulias V (2015) Prognostic significance of serum inflammatory response markers in newly diagnosed non-small cell lung cancer before chemoirradiation. Biomed Res Int 2015:485732. doi:10.1155/2015/485732 PubMedPubMedCentral Tolia M, Tsoukalas N, Kyrgias G, Mosa E, Maras A, Kokakis I, Liakouli Z, Kouvaris JR, Liaskonis K, Charalampakis N, Pistevou-Gombaki K, Kelekis N, Kouloulias V (2015) Prognostic significance of serum inflammatory response markers in newly diagnosed non-small cell lung cancer before chemoirradiation. Biomed Res Int 2015:485732. doi:10.​1155/​2015/​485732 PubMedPubMedCentral
Zurück zum Zitat Tomita M, Ayabe T, Chosa E, Nakamura K (2014) Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res 34(6):3137–3140PubMed Tomita M, Ayabe T, Chosa E, Nakamura K (2014) Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res 34(6):3137–3140PubMed
Zurück zum Zitat Wicker N, Carles A, Mills IG, Wolf M, Veerakumarasivam A, Edgren H, Boileau F, Wasylyk B, Schalken JA, Neal DE, Kallioniemi O, Poch O (2007) A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genom 8:84. doi:10.1186/1471-2164-8-84 CrossRef Wicker N, Carles A, Mills IG, Wolf M, Veerakumarasivam A, Edgren H, Boileau F, Wasylyk B, Schalken JA, Neal DE, Kallioniemi O, Poch O (2007) A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genom 8:84. doi:10.​1186/​1471-2164-8-84 CrossRef
Metadaten
Titel
Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer
verfasst von
Heng Fan
Zhen-Yi Shao
Yuan-Yuan Xiao
Zhi-Hui Xie
Wen Chen
Hua Xie
Guo-You Qin
Nai-Qing Zhao
Publikationsdatum
11.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2113-0

Weitere Artikel der Ausgabe 6/2016

Journal of Cancer Research and Clinical Oncology 6/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.